Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 6/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 3/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19833759 | 0.92 | MAP3K5 (0.42) | NR3C2NR3C1MAP3K5MGLLPGR | |
| SCHEMBL19847887 | 0.90 | NR3C2 (0.40) | NR3C2NR3C1MAP3K5MGLLPGR | |
| SCHEMBL19833864 | 0.90 | NR3C2 (0.45) | NR3C2NR3C1MAP3K5MGLLPGR | |
| SCHEMBL19834105 | 0.90 | MGLL (0.43) | NR3C2NR3C1MAP3K5MGLLPGR | |
| SCHEMBL19833835 | 0.88 | CPS1 (0.41) | NR3C2NR3C1MAP3K5PGRDHODH | |
| SCHEMBL19833872 | 0.87 | MGLL (0.51) | NR3C2NR3C1MAP3K5MGLLPGR | |
| SCHEMBL19833873 | 0.86 | MAP3K5 (0.43) | NR3C2NR3C1MAP3K5PGRTRPV1 | |
| SCHEMBL19833912 | 0.85 | NR3C2 (0.39) | NR3C2NR3C1MAP3K5MGLLPGR | |
| SCHEMBL19834174 | 0.82 | MGLL (0.49) | NR3C2NR3C1MAP3K5MGLLPGR | |
| SCHEMBL19833904 | 0.80 | MGLL (0.57) | NR3C2NR3C1MGLLPGRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3279191-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-10106556-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-23 | — | — | US | disclosed |
| US-20180079756-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3279191-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079756-A1 | HETEROCYCLIC COMPOUND | MAG, ACHE, HTT | NR3C2 2434/4885NR3C1 1340/4885MAP3K5 1965/4885 |
| US-10106556-B2 | Heterocyclic compound | MAG, ACHE, HTT | NR3C2 2434/4885NR3C1 1340/4885MAP3K5 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.